DK3141617T3 - Fremgangsmåde til at forudsige udfaldet af en kræft hos en patient ved at analysere geneekspression - Google Patents

Fremgangsmåde til at forudsige udfaldet af en kræft hos en patient ved at analysere geneekspression Download PDF

Info

Publication number
DK3141617T3
DK3141617T3 DK16193596.0T DK16193596T DK3141617T3 DK 3141617 T3 DK3141617 T3 DK 3141617T3 DK 16193596 T DK16193596 T DK 16193596T DK 3141617 T3 DK3141617 T3 DK 3141617T3
Authority
DK
Denmark
Prior art keywords
gene cluster
combination
particular embodiment
gnly
ren
Prior art date
Application number
DK16193596.0T
Other languages
English (en)
Inventor
Franck Pages
Bernard Mlecnik
Herve Fridman
Jérôme Galon
Original Assignee
Inst Nat Sante Rech Med
Univ Paris Descartes
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Paris Descartes, Hopitaux Paris Assist Publique filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK3141617T3 publication Critical patent/DK3141617T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Claims (11)

1. Fremgangsmåde til at forudsige udfaldet af en kræft hos en patient omfattende et trin bestående af at bestemme ekspressionsniveauet af en genklynge i en prøve opnået fra nævnte patient, hvor nævnte genklynge omfatter mindst 5 gener valgt fra gruppen bestående af GZMH, IFNG, CXCL13, GNLY, LAG3, ITGAE, CCL5, CXCL9, PF4, IL17A, TSLP, REN, IHH, PROM1 og VEGFA.
2. Fremgangsmåden til at forudsige udfaldet afen kræft hos en patient ifølge krav 1, hvor nævnte genklynge omfatter 6 gener valgt fra gruppen bestående af GZMH, IFNG, CXCL13, GNLY, LAG3, ITGAE, CCL5, CXCL9, PF4, IL17A, TSLP, REN, IHH, PROM1 og VEGFA.
3. Fremgangsmåden til at forudsige udfaldet afen kræft hos en patient ifølge krav 1, hvor nævnte genklynge omfatter 7 gener valgt fra gruppen bestående af GZMH, IFNG, CXCL13, GNLY, LAG3, ITGAE, CCL5, CXCL9, PF4, IL17A, TSLP, REN, IHH, PROM1 og VEGFA.
4. Fremgangsmåden til at forudsige udfaldet afen kræft hos en patient ifølge krav 1, hvor nævnte genklynge omfatter 8 gener valgt fra gruppen bestående af GZMH, IFNG, CXCL13, GNLY, LAG3, ITGAE, CCL5, CXCL9, PF4, IL17A, TSLP, REN, IHH, PROM1 og VEGFA.
5. Fremgangsmåden til at forudsige udfaldet afen kræft hos en patient ifølge krav 1, hvor nævnte genklynge omfatter 9 gener valgt fra gruppen bestående af GZMH, IFNG, CXCL13, GNLY, LAG3, ITGAE, CCL5, CXCL9, PF4, IL17A, TSLP, REN, IHH, PROM1 og VEGFA.
6. Fremgangsmåden til at forudsige udfaldet afen kræft hos en patient ifølge krav 1, hvor nævnte genklynge omfatter 10 gener valgt fra gruppen bestående af GZMH, IFNG, CXCL13, GNLY, LAG3, ITGAE, CCL5, CXCL9, PF4, IL17A, TSLP, REN, IHH, PROM1 og VEGFA.
7. Fremgangsmåden til at forudsige udfaldet afen kræft hos en patient ifølge krav 1, hvor nævnte genklynge omfatter 11 gener valgt fra gruppen bestående af GZMH, IFNG, CXCL13, GNLY, LAG3, ITGAE, CCL5, CXCL9, PF4, IL17A, TSLP, REN, IHH, PROM1 og VEGFA.
8. Fremgangsmåden til at forudsige udfaldet afen kræft hos en patient ifølge krav 1, hvor nævnte genklynge omfatter 12 gener valgt fra gruppen bestående af GZMH, IFNG, CXCL13, GNLY, LAG3, ITGAE, CCL5, CXCL9, PF4, IL17A, TSLP, REN, IHH, PROM1 og VEGFA.
9. Fremgangsmåden til at forudsige udfaldet afen kræft hos en patient ifølge krav 1, hvor nævnte genklynge omfatter 13 gener valgt fra gruppen bestående af GZMH, IFNG, CXCL13, GNLY, LAG3, ITGAE, CCL5, CXCL9, PF4, IL17A, TSLP, REN, IHH, PROM1 og VEGFA.
10. Fremgangsmåden til at forudsige udfaldet afen kræft hos en patient ifølge krav 1, hvor nævnte genklynge omfatter 14 gener valgt fra gruppen bestående af GZMH, IFNG, CXCL13, GNLY, LAG3, ITGAE, CCL5, CXCL9, PF4, IL17A, TSLP, REN, IHH, PROM1 og VEGFA.
11. Anvendelse af et kit omfattende organ til at specifikt måle ekspressionsniveauet af mindst fem gener i en biologisk prøve til at udføre fremgangsmåden ifølge krav 1, hvor nævnte mindst fem gener er valgt fra gruppen bestående af GZMH, IFNG, CXCL13, GNLY, LAG3, ITGAE, CCL5, CXCL9, PF4, IL17A, TSLP, REN, IHH, PROM1 og VEGFA.
DK16193596.0T 2011-01-11 2012-01-11 Fremgangsmåde til at forudsige udfaldet af en kræft hos en patient ved at analysere geneekspression DK3141617T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305024 2011-01-11
US201161434514P 2011-01-20 2011-01-20
EP12700803.5A EP2663650B1 (en) 2011-01-11 2012-01-11 Methods for predicting the outcome of a cancer in a patient by analysing gene expression

Publications (1)

Publication Number Publication Date
DK3141617T3 true DK3141617T3 (da) 2019-02-25

Family

ID=43778393

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16193596.0T DK3141617T3 (da) 2011-01-11 2012-01-11 Fremgangsmåde til at forudsige udfaldet af en kræft hos en patient ved at analysere geneekspression

Country Status (8)

Country Link
US (4) US20140018255A1 (da)
EP (2) EP2663650B1 (da)
JP (1) JP6505656B2 (da)
DK (1) DK3141617T3 (da)
ES (1) ES2609249T3 (da)
LT (1) LT3141617T (da)
PL (1) PL3141617T3 (da)
WO (1) WO2012095448A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2880180B1 (en) * 2012-08-06 2018-10-03 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and kits for screening patients with a cancer
GB202209539D0 (en) 2017-06-13 2022-08-10 Bostongene Corp Systems and methods for identifying cancer treatments from normalized biomarker scores
US10704093B2 (en) 2017-07-05 2020-07-07 The Regents Of The Universtiy Of California Assay for pre-operative prediction of organ function recovery
GB201810190D0 (en) * 2018-06-21 2018-08-08 Cancer Research Tech Ltd Prognostic and treatment response predictive method
SG11202112712RA (en) 2019-06-03 2021-12-30 Inst Nat Sante Rech Med Methods for modulating a treatment regimen
WO2021092071A1 (en) 2019-11-07 2021-05-14 Oncxerna Therapeutics, Inc. Classification of tumor microenvironments
US20230235408A1 (en) 2020-06-30 2023-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
EP4172628A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
CA3193688A1 (en) * 2020-10-09 2022-04-14 Vladimir Lazar Novel prediction method and gene signatures for the treatment of cancer
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773883B2 (en) * 2000-07-31 2004-08-10 The Brigham & Women's Hospital, Inc. Prognostic classification of endometrial cancer
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
WO2005071419A2 (en) * 2004-01-16 2005-08-04 Ipsogen Protein expression profiling and breast cancer prognosis
US20080268476A1 (en) * 2004-05-12 2008-10-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (N4) as a Marker for Cancer Prognosis
JP4370409B2 (ja) * 2005-06-22 2009-11-25 国立大学法人東北大学 がんの予後予測方法
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
BRPI0618597A2 (pt) * 2005-11-14 2011-09-06 Bayer Healthcare Llc métodos de predição e prognóstico de cáncer e método de monitoramento de terapia contra o cáncer
EP2061885A4 (en) * 2006-09-15 2011-03-09 Univ Mcgill STROMA-DERIVED PREDICTOR FOR BREAST CANCER
JP5773315B2 (ja) * 2008-11-27 2015-09-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 膵癌のバイオマーカーとしてのｃｘｃｌ４ｌ１
EP2213682A1 (en) * 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
WO2010144192A1 (en) * 2009-05-05 2010-12-16 Children's Medical Center Corporation Prognosis indicators for solid human tumors

Also Published As

Publication number Publication date
US20150225799A1 (en) 2015-08-13
US20170175207A1 (en) 2017-06-22
JP6051166B2 (ja) 2016-12-27
JP2014506782A (ja) 2014-03-20
ES2609249T3 (es) 2017-04-19
EP2663650A1 (en) 2013-11-20
JP6505656B2 (ja) 2019-04-24
EP3141617B1 (en) 2018-11-14
JP2017060515A (ja) 2017-03-30
EP2663650B1 (en) 2016-11-09
EP3141617A2 (en) 2017-03-15
WO2012095448A1 (en) 2012-07-19
PL3141617T3 (pl) 2019-04-30
US20200248269A1 (en) 2020-08-06
EP3141617A3 (en) 2017-04-19
US20140018255A1 (en) 2014-01-16
LT3141617T (lt) 2019-02-25

Similar Documents

Publication Publication Date Title
DK3141617T3 (da) Fremgangsmåde til at forudsige udfaldet af en kræft hos en patient ved at analysere geneekspression
ES2525382T3 (es) Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino
JP6246845B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
KR20120065959A (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
JP2020500515A (ja) 乳がん患者の予後の予測方法
JP6240258B2 (ja) ｍｉＲＮＡの発現を分析することによって大腸癌の転帰を予測するための方法
JP2011509689A (ja) Ｉｉ及びｉｉｉ期結腸癌の分子病期分類並びに予後診断
US20160222461A1 (en) Methods and kits for diagnosing the prognosis of cancer patients
US11840733B2 (en) Method for predicting prognosis of breast cancer patient
CN102361990A (zh) 通过监测两种基因的表达的乳腺癌患者的预后
WO2013172947A1 (en) Method and system for predicting recurrence and non-recurrence of melanoma using sentinel lymph node biomarkers
US20150329911A1 (en) Nucleic acid biomarkers for prostate cancer
US20210147944A1 (en) Methods for monitoring and treating prostate cancer
JP6051166B6 (ja) 遺伝子の発現を分析することによって患者における癌の転帰を予測するための方法
ES2709357T3 (es) Métodos de predicción del desenlace de un cáncer en un paciente analizando la expresión génica
WO2011097519A2 (en) Methods and kits used in classifying adrenocortical carcinoma